Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMAFortunato Morabito, Michèle Cavo, Massimo Gentile et al.|European Journal Of Haematology|2009Cited by 81
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Pellegrino Musto, Catello Califano et al.|Haematologica|2023Cited by 19
Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.Michèle Cavo, Michele Baccarani, Nicoletta Testoni et al.|Blood|2008Cited by 10
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Pellegrino Musto, Salvatore Palmieri et al.|Hematological Oncology|2024Cited by 7
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter StudyMassimo Gentile, Fortunato Morabito, Stefania Ciolli et al.|Blood|2008Cited by 2